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ABSTRACTS A.13 
or hospital), and the MICs as determined by the broth microdilution method. In this preliminary analysis of 39 sites across 
the US, the non-susceptibility of S. pneumoniue to penicillin closely matched that of recent national surveillance studies with 
intermediate non-susceptibility of 31% and high-level penicillin resistance of 14%. Among the antibiotics tested, the 
quinolones were the most active; against S. pneumoniae, moxifloxacin was more active than trovafloxacin, which was more 
active than levofloxacin. These data outline an effective approach to generating comparative regional and national 
susceptibility data against the common respiratory tract pathogens. 
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Aims: The aim of the study was to verify the role of Chlamydia pneumoniae in the aethiology of CAP 
Material and method: we prospectively analyzed case histories, medical records and investigations of Chlamydia pneumoniae 
antibodies in 70 hospitalized CAP patients (mean age 48 yrs.) in the Tartu University Lung Hospital in 1999. Clamydia 
pneumoniae antibodies were measured by ELISA method and the results were presented in enzyme immune units (EIU). The 
signs of acute infection (IgA>8, and/or positive IgMr1.1, IgGs30 EIU) were found in 44 patients (63%), (mean age 52 yrs.) 
The mean value for IgA was 41.9 EIU (ranging from 10 to 179), and for IgG 132.3 EIU (ranging from 31 to 383.8). 26 
patients (mean age 40 yrs.) did not satisfy the criteria of Chlumydia pneumoniae infection. There were no Chlamydia 
pneumoniue antibodies in 19 (27%) of patients, IgG antibody was identified in 7 (10%) of patients. 
A second concurrent respiratory pathogen (Mycoplasma pneumoniae, B. pertussis or other typical bacteria) was found in 17 
(39%) acute Chlamydiapneumoniae cases. All patients predominately suffered from acute clinical symptoms. 
In conclusion: Chlamydia pneumoniae is an important aethiological agent in hospitalized CAP patients in our hospital, mainly 
in patients 50 years and over. 
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Quantitative BAL is an accepted diagnostic tool in nosocomial and ventilator associated pneumonia-the position of this 
bronchoscopic technique in CAP however is unclear. Between 1992 and 1996 149 patients (68.5% males) with finally 
diagnosed CAP underwent BAL. BAL passed for positive if the following criterias were fulfilled: 104 cfu/ml or qualitative 
proof of P carinii. A positive bacteriological diagnosis by BAL was possible in 48.3% of these patients. Leading pathogens 
were Gram-positive cocci (14.8%) and l? carinii (14.8%) followed by H. inzuenca (9.4%). A previous antibiotic therapy did not 
reduce positive BAL results (47.3% vs. 50.0%). Complications of bronchoscopy were temporary. Results of BAL induced a 
change of antibiotic treatment in 85.0% of patients with positive BAL findings. Quantitative BAL contributes significantly to 
a precise diagnosis and treatment of CAP 
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The bactericidal activity of the fluoroquinolones (FLQs) levofloxacin (LEV), ciprofloxacin (CIP), ofloxacin (OFL), 
moxifloxacin (MOX) or grepafloxacin (GRE) between 0.003 and 200 mg/l was assessed in Mueller Hinton broth (& 5% (v/v) 
lysed horse blood) over 3 h at 37 “C. Three penicillin-susceptible clinical isolates of S. pneumoniae (SP) were used; SP 007 
(OFL MIC 1 mg/l); SP 303 (OFL MIC 4 mg/l) and SP 181 (OFL MIC 32 mg/l). After incubation, viable counts were made on 
blood agar and log change in viability was plotted against log drug concentration. Kill was compared relative to individual 
drug pharmacokinetics by calculating bactericidal indices (BIs) from these plots (J Antimicrob Chemother 1997, 39: 713). BIs 
were calculated as the AUC of each kill curve at bactericidal concentrations up to serum Cmax (Smax) or lung tissue Cmax 
(Lmax) using data from published literature after single 400 or 500 mg oral doses. 
